GRIK2

Glutamate receptor ionotropic, kainate 2 · Q13002 · GRIK2 on Sugi Atlas →

54,497 patent compounds predicted against GRIK2, 31,123 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Kainic Acid (SCHEMBL15777)	1.00	15/20
SCHEMBL30895	0.69	12/20
SCHEMBL71719	0.69	12/20
Hydrochloric Acid (SCHEMBL74585)	0.66	11/20
Leucine (SCHEMBL122270)	0.44	8/20
Leucine (SCHEMBL122271)	0.44	8/20
SCHEMBL188081	0.44	8/20
SCHEMBL188082	0.44	8/20
Leucine (SCHEMBL138874)	0.41	8/20
Aspartic Acid (SCHEMBL135731)	0.50	7/20
SCHEMBL139672	0.56	6/20
Leucine (SCHEMBL175940)	0.52	6/20
Leucine (SCHEMBL175941)	0.52	6/20
SCHEMBL197664	0.40	6/20
SCHEMBL40728	0.58	5/20
Asparagine (SCHEMBL15460)	0.54	5/20
Asparagine (SCHEMBL38379)	0.54	5/20
Asparagine (SCHEMBL150535)	0.54	5/20
SCHEMBL151676	0.48	5/20
SCHEMBL197013	0.48	5/20

Clinical trials — most relevant to GRIK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD	PHASE2	RECRUITING
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203	PHASE1	COMPLETED
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy)	nan	UNKNOWN
(GluEsk) Glutamate and Esketamine	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
Post-stroke Epilepsy: Primary Prophylaxis Study	nan	UNKNOWN
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis	nan	RECRUITING
Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis	nan	COMPLETED
Acamprosate: Genes Associated With Response	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIK2 binder may also engage these)

Protein	Name	Similarity
P39087	—	1.000	P39087 →
P42260	—	1.000	P42260 →
Q38PU3	—	1.000	Q38PU3 →
Q38PU2	—	1.000	Q38PU2 →
Q91755	—	1.000	Q91755 →
B1AS29	—	1.000	B1AS29 →
P42264	—	1.000	P42264 →
Q9Z2W8	—	1.000	Q9Z2W8 →
A0A2R8QF68	—	1.000	A0A2R8QF68 →
GRIK3	Glutamate receptor ionotropic, kainate 3	1.000	landscape →
GRIK1	Glutamate receptor ionotropic, kainate 1	0.999	landscape →
GRIA2	Glutamate receptor 2	0.999	landscape →
GRIA4	Glutamate receptor 4	0.999	landscape →
Q38PU4	—	0.998	Q38PU4 →
Q38PU5	—	0.998	Q38PU5 →
P23819	—	0.998	P23819 →
P19492	—	0.997	P19492 →
GRIA1	Glutamate receptor 1	0.997	landscape →
Q60934	—	0.997	Q60934 →
Q5R4M0	—	0.996	Q5R4M0 →
Q38PU8	—	0.996	Q38PU8 →
P19493	—	0.995	P19493 →
P22756	—	0.995	P22756 →
GRIA3	Glutamate receptor 3	0.995	landscape →
P19491	—	0.995	P19491 →
Q38PU6	—	0.995	Q38PU6 →
P19490	—	0.994	P19490 →
P23818	—	0.994	P23818 →
Q38PU7	—	0.994	Q38PU7 →
P26591	—	0.994	P26591 →